Neurognostics, Inc.: Len Seward Joins Neurognostics as Vice President of Sales

CONTACT:
Douglas M. Tucker, PhD, MBA
Neurognostics, Inc.

Phone: 414-727-7950 x 110
Fax: 414-727-7952
E-mail: [email protected]
Website: www.neurognostics.com

Milwaukee, WI, July 28, 2005 – Neurognostics, Inc., a company specializing in functional Magnetic Resonance Imaging (fMRI) products and services, is pleased to announce Len Seward as new Vice President of Sales. With over 17 years of experience in medical device sales, Seward brings a distinguished track record of industry experience in sales and marketing.

As a key member of Neurognostics’ executive team, Seward is responsible for expanding the sales of Neurognostics’ MindState product line through direct and indirect channels, leveraging his experience in building start-up sales, and building a sales team to accommodate nationwide sales of the company’s products and services.

“We are very pleased to have Len join our team,” said Neurognostics’ CEO, Douglas Tucker, PhD, MBA, “His talents and skills are a great match to the next stage in our growth and continued expansion. Len has consistently demonstrated his abilities at several successful medical device companies and we are confident that his knowledge and experience will be helpful in driving the company’s ongoing success.”

Seward previously held positions with Advanced Bionics (Division of Boston Scientific), Medtronic Neurological and United States Surgical Corporation. He received his BA in Economics and a minor in Business Administration from Eastern Illinois University.

Founded in 2003, Neurognostics strives to enhance the quality of life for millions of patients suffering from disorders of the central nervous system (CNS) by developing, validating, and implementing applications that release the clinical power of fMRI. fMRI is a powerful imaging technique that extends the capability of Magnetic Resonance (MR) imaging by providing information about the functioning of imaged tissue. The Company hopes that its applications will become the standard technique to assess and manage patients with CNS disorders.